Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares reached a new 52-week low on Tuesday. The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 8,100 shares traded. The stock had previously closed at C$0.03.
Quest PharmaTech Trading Down 20.0%
The company has a market cap of C$3.38 million, a P/E ratio of 0.68 and a beta of -0.61. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35. The firm’s 50-day moving average price is C$0.02 and its 200-day moving average price is C$0.03.
About Quest PharmaTech
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Further Reading
- Five stocks we like better than Quest PharmaTech
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
- D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?
- 5 AI Heavyweights That Look Too Cheap to Ignore After the Sell-Off
- Bonds Are Paying 5% Again, and the Repricing Has Reached Every Corner of the Market
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
